Abstract:Natural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the "hallmarks of cancer" are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability.

MNK: A Novel Promising Target for Cancer Immunotherapy

Progress in developing MNK inhibitors

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Enhanced Anti-Tumor Response Upon Deficiency of Msn Kinase MINK1 in Mice

NK Cell Therapy: A Rising Star in Cancer Treatment

Immune Checkpoint Molecules in Natural Killer Cells As Potential Targets for Cancer Immunotherapy.

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia

NK Cell-Based Immunotherapy for Malignant Diseases

NK cell-based cancer immunotherapy: from basic biology to clinical application.

Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors

MNK1/2 Inhibition Limits Oncogenicity and Metastasis of KIT-mutant Melanoma

Design, synthesis and biological evaluation of MNK-PROTACs

Immune Evasion and Therapeutic Opportunities Based on Natural Killer Cells.

The Advances and Challenges of NK Cell-Based Cancer Immunotherapy

Targeting Protein Kinases Benefits Cancer Immunotherapy.

Mitogen-Activated Protein Kinase (MAPK): New Insights in Breast Cancer

The basic biology of NK cells and its application in tumor immunotherapy

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

Natural killer cells in cancer biology and therapy

Nanoengineered Targeting Strategy for Cancer Immunotherapy

Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects